Video

Dr. Leslie on the 3-Year Follow-Up of the ZUMA-5 Trial in R/R iNHL

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial (NCT03105336) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).

The phase 2 trial is evaluating patients with relapsed/refractory iNHL who are treated with the CAR T-cell therapy, axicabtagene ciloleucel (axi-cel; Yescarta).

Based on previous data, it appears that axi-cel is a durable option for patients with relapsed or refractory indolent lymphoma, Leslie notes. The 3-year progression-free survival rate was 65% and the 3-year lymphoma-specific survival rate was 89%, indicating that patients can have durable responses following a single CAR T infusion, Leslie says.

Additionally, more patients with marginal zone lymphoma are being observed, and their overall survival has improved, Leslie continues. Although axi-cel is not yet FDA approved for patients with marginal zone lymphoma, the NCCN has recommended axi-cel for patients who have received 2 or more prior lines of therapy, Leslie concludes.

Related Videos
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute
Manali Kamdar, MD
Ibrahim Aldoss, MD